viewCytoDyn Inc.

CytoDyn files second clinical trial protocol to treat severely ill coronavirus patients with lernlimab

The trial is designed to measure the mortality rate in patients with severe cases after two weeks

Person wearing medical mask and nursing cap holding a vial of blood labeled 'coronavirus'
Leronlimab is designed to help fight the coronavirus by treating its respiratory symptoms and the accompanying cytokine storm

CytoDyn Inc (OTCQB:CYDY) said it has filed a second clinical trial protocol with the US Food and Drug Administration (FDA), this time to treat severely ill coronavirus (COVID-19) patients with its drug leronlimab. 

The trial will be conducted under the same FDA-approved Investigational New Drug application that the company used to recently launch a Phase 2 trial of patients with mild-to-moderate symptoms. 

The plan is to enroll patients in both protocols as quickly as possible. Severely ill patients will receive leronlimab for two weeks, with the primary endpoint of the study being the 14-day mortality rate.

READ: CytoDyn’s Phase 2 trial to treat mild-to-moderately ill coronavirus patients with leronlimab cleared by the FDA

Once a coronavirus patient needs a ventilator, the mortality rate becomes very high, CEO Nader Pourhassan noted in a statement. Leronlimab is designed to help by treating the respiratory symptoms caused by the virus.

“Once again, the FDA continues to be very supportive of everyone’s efforts to increase access to leronlimab in order to assess its therapeutic benefits for a broader range of COVID-19 patients,” Pourhassan said.

"With a study in China indicating the mortality rate among COVID-19 patients requiring mechanical ventilators at more than 85%, the world desperately needs a therapy that can help this patient population.”

The company has already administered leronlimab to 10 severely ill patients at a medical facility in New York, separate from the coming trial.

An evaluation from diagnostics company IncellDx of the first four of those patients noted “immunological benefits within three days” following treatment with leronlimab, and “lower level of cytokine storm, especially IL-6 and TNF-α, which were reduced significantly.”

A cytokine storm occurs when the body overproduces immune cells and their activating compounds, known as cytokines. The overproduction can cause inflammation in the lungs and fluid build-up, which can lead to respiratory issues and be contaminated by a secondary bacterial pneumonia, according to The Scripps Research Institute.

In addition to its use as a potential coronavirus treatment, leronlimab has other therapeutic indications as a treatment for HIV and certain breast cancers.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: CytoDyn Inc.

Price: 3.1 USD

Market: OTCQB
Market Cap: $1.49 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...



CytoDyn to work with Mexican National Institutes of Health to treat...

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan tells Proactive the biotech has plans to work with the Mexican National Institutes of Health on a trial of leronlimab for severe coronavirus patients in the country. Pourhassan says the initial trial is expected to include about 30 patients. After...

5 days, 7 hours ago

2 min read